Published in Aliment Pharmacol Ther on September 01, 2005
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut (2006) 2.33
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.63
Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci (2007) 1.27
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology (2008) 1.14
Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome. Ann Gastroenterol (2014) 1.02
Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Manag (2008) 1.00
Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis (2009) 0.93
New treatments for irritable bowel syndrome in women. Womens Health (Lond Engl) (2008) 0.88
Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis. PLoS One (2015) 0.85
The treatment of irritable bowel syndrome. Therap Adv Gastroenterol (2009) 0.84
Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol (2014) 0.83
Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. J Gastroenterol (2012) 0.83
Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil (2013) 0.83
Bloating and functional gastro-intestinal disorders: where are we and where are we going? World J Gastroenterol (2014) 0.80
Irritable bowel syndrome: a review article. Middle East J Dig Dis (2010) 0.78
Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig Dis Sci (2014) 0.77
Management Strategies for Abdominal Bloating and Distension. Gastroenterol Hepatol (N Y) (2014) 0.76
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology (2015) 0.75
Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil (2016) 0.75
History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Prim Care Companion J Clin Psychiatry (2008) 0.75
Fluoxetine in the treatment of irritable bowel syndrome. J Res Pharm Pract (2013) 0.75
Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer (2008) 2.79
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract (2010) 2.57
Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer (2004) 2.46
Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2008) 2.43
Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther (2012) 2.09
Validity and reliability of a new food frequency questionnaire compared to 24 h recalls and biochemical measurements: pilot phase of Golestan cohort study of esophageal cancer. Eur J Clin Nutr (2006) 2.03
Coeliac disease presenting with symptoms of irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.99
Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol (2004) 1.72
Golestan cohort study of oesophageal cancer: feasibility and first results. Br J Cancer (2005) 1.54
Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut (2007) 1.52
Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther (2001) 1.27
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther (2001) 1.26
Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol (1997) 1.25
Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. Cochrane Database Syst Rev (2006) 1.19
Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study. J Viral Hepat (2013) 1.19
Coeliac disease in Middle Eastern countries: a challenge for the evolutionary history of this complex disorder? Dig Liver Dis (2004) 1.19
Pneumatic balloon dilatation in achalasia: a prospective comparison of safety and efficacy with different balloon diameters. Aliment Pharmacol Ther (2004) 1.15
Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther (2003) 1.12
Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther (2008) 1.12
Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J (2010) 1.11
Images of interest. Gastrointestinal: polypoid arteriovenous malformation of the colon. J Gastroenterol Hepatol (2004) 1.09
Coeliac disease in Iranian type I diabetic patients. Dig Liver Dis (2004) 1.03
High-fat, high-cholesterol diet increases the incidence of gastritis in LDL receptor-negative mice. Arterioscler Thromb Vasc Biol (2001) 1.02
Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther (2004) 1.00
Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. J Viral Hepat (2008) 0.98
High incidence of adenocarcinoma arising from the right side of the gastric cardia in NW Iran. Gut (2004) 0.96
Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene (2007) 0.96
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Ann Oncol (2006) 0.94
Endoscopic esophageal cancer survey in the western part of the Caspian Littoral. Dis Esophagus (2002) 0.93
Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion (2001) 0.92
Investigation of NQO1 genetic polymorphism, NQO1 gene expression and PAH-DNA adducts in ESCC. A case-control study from Iran. Genet Mol Res (2010) 0.90
Lower oesophageal sphincter pressure and timed barium oesophagogram: two objective parameters in the non-invasive assessment of primary achalasia. Aliment Pharmacol Ther (2005) 0.89
Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial. Aliment Pharmacol Ther (2006) 0.88
Esophageal cancer in northeastern Iran. Indian J Gastroenterol (2005) 0.87
Orientation of cobra alpha-toxin on the nicotinic acetylcholine receptor. Fluorescence studies. J Biol Chem (1990) 0.86
Gastric atrophy and oesophageal squamous cell carcinoma: possible interaction with dental health and oral hygiene habit. Br J Cancer (2012) 0.86
Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol (2001) 0.85
Ethanolamine oleate as a novel therapy is effective in resistant idiopathic achalasia. Dis Esophagus (2013) 0.85
Changing epidemiology of IPSID in Southern Iran. Gut (2005) 0.85
Tuberculous peritonitis in an endemic area. Dig Liver Dis (2003) 0.82
Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer (2006) 0.82
Large body size and sedentary lifestyle during childhood and early adulthood and esophageal squamous cell carcinoma in a high-risk population. Ann Oncol (2011) 0.81
Effect of Helicobacter pylori eradication or of ranitidine plus metoclopramide on Helicobacter pylori-positive functional dyspepsia. A randomized, controlled follow-up study. Digestion (2002) 0.81
Identification of Hepatitis B Virus Surface Antigen (HBsAg) Genotypes and Variations in Chronic Carriers from Isfahan Province, Iran. Iran J Public Health (2012) 0.80
Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of Helicobacter pylori. East Mediterr Health J (2006) 0.80
[Epidemiology of war injuries, about two conflicts: Iraq and Afghanistan]. Ann Fr Anesth Reanim (2011) 0.79
Lipoprotein modification and atherosclerosis in aging. Exp Gerontol (1999) 0.77
Efficacy of botulinum toxin injection before pneumatic dilatation in patients with idiopathic achalasia. Dis Esophagus (2004) 0.76
A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates. J Gastroenterol Hepatol (2001) 0.76
Letter: The reversal of liver cirrhosis--what we know and what we need to know--authors' reply. Aliment Pharmacol Ther (2013) 0.75
Intratracheal instillation of epinephrine in life-threatening hemoptysis. Minerva Anestesiol (2011) 0.75
Adverse cardiac events during catecholamine therapy: a role for hydrocortisone? Intensive Care Med (2012) 0.75
Cytopathology of alpha chain disease involving the central nervous system and pleura. Acta Cytol (1989) 0.75
Antimicrobial effectiveness of ketoconazole against metronidazole-resistant Helicobacter pylori isolates from Iranian dyspeptic patients. J Antimicrob Chemother (2006) 0.75
Education and imaging. Gastrointestinal: pancreatic tuberculosis masquerading as malignancy. J Gastroenterol Hepatol (2014) 0.75
[Perioperative management of a patient with an acquired von Willebrand syndrome]. Ann Fr Anesth Reanim (2007) 0.75
Common variable immunodeficiency: endoscopic and pathological findings. Endoscopy (2004) 0.75
Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol (2012) 0.75
Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin. Eur J Gastroenterol Hepatol (1998) 0.75
Synthesis of N-beta-D-glucopyranosyl derivatives of barbital, phenobarbital, metharbital, and mephobarbital. Carbohydr Res (1989) 0.75